Sign up to save your podcasts
Or
Share Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
View all episodes
By Bernard Marini, Anthony Perissinotti, et al.
4.5
3030 ratings
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
More shows like WolverHeme Happy Hour
View all
Fresh Air
38,484 Listeners
The NPR Politics Podcast
25,791 Listeners
Pod Save America
87,126 Listeners
The Daily
111,863 Listeners
Up First from NPR
56,489 Listeners
OncoPharm
187 Listeners
Today, Explained
10,215 Listeners
Interesting Times with Ross Douthat
7,226 Listeners
Blood Podcast
52 Listeners
ASTCT Talks
8 Listeners
The Ezra Klein Show
15,815 Listeners
The Weekly Show with Jon Stewart
10,717 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
192 Listeners
The Headlines
615 Listeners